Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed advanced malignant solid
             tumor that has recurred or progressed following standard therapy, or that has not
             responded to standard therapy, or for which there is no standard therapy, or who are
             not candidates for standard therapy

          -  Patients must be > 18 years of age

          -  Patients of their legal representatives must be able to understand and sign an
             informed consent form

          -  Patients must have evaluable or measurable tumor(s)

          -  Patients must be recovered from the effects of any prior surgery, radiotherapy or
             other antineoplastic therapy. Up to CTCAE Grade 1 is acceptable for patients with
             known peripheral neuropathy

          -  Women of childbearing potential as well as fertile men and their partners must agree
             to abstain from sexual intercourse or to use an effective form of contraception during
             the study and for 90 days following the last dose of MM-151 (an effective form of
             contraception is an oral contraceptive or a double barrier method)

        Exclusion Criteria:

          -  Patients for whom potentially curative antineoplastic therapy is available

          -  Patients who are pregnant or lactating

          -  Patients with an active infection or with an unexplained fever > 38.5°C during
             screening visits or on the first scheduled day of dosing. (At the discretion of the
             investigator, patients with tumor fever may be enrolled.)

          -  Patients with untreated and/or symptomatic CNS malignancies (primary or metastatic);
             patients with CNS metastases who have undergone surgery or radiotherapy, whose disease
             is stable, and who have been on a stable dose of corticosteroids for at least 2 weeks
             prior to the first scheduled day of dosing will be eligible for the trial